Apellis reports mixed results for pegcetacoplan for geographic atrophy

Apellis Pharmaceuticals reported topline results from two phase 3 studies investigating pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration, according to a press release.
DERBY and OAKS are multicenter, randomized, double-masked, sham-controlled studies investigating the efficacy and safety of intravitreal pegcetacoplan.
OAKS met its primary endpoint at 12 months, showing statistical significance in monthly and every other month injections by demonstrating a reduction in GA lesion growth of 22% (P = .0003) and 16% (P = .005), respectively, compared

Full Story →